

Supplementary Table S2: Concomitant medications starting before/after TMZ administration from the ITTS (>10%) by treatment sequence and totaled over all patients.

Concomitant medications, ATC term >10%	Ped-TMZ oral suspension — TMZ oral capsule (n=17)			TMZ oral capsule — Ped-TMZ oral suspension (n=19)			Overall (N=36)		
	n	%	E	n	%	E	n	%	E
CLOBAZAM	2	11.8	2	0	0	0	2	5.6	2
LACOSAMIDE	3	17.6	3	2	10.5	2	5	13.9	5
LAMOTRIGINE	2	11.8	2	0	0	0	2	5.6	2
LEVETIRACETAM	3	17.6	3	8	42.1	8	11	30.6	11
METFORMINE	3	17.6	3	0	0	0	3	8.3	3
PANTOPRAZOLE	3	17.6	3	1	5.3	1	4	11.1	4
PARACETAMOL	2	11.8	2	1	5.3	1	3	8.3	3
PREDNISOLONE	7	41.2	7	2	10.5	2	9	25.0	9
SULFAMETHOXAZOLE; TRIMETHOPRIM	0	0	0	2	10.5	2	2	5.6	2
TELMISARTAN	0	0	0	2	10.5	2	2	5.6	2

%, percentage of patients, ATC, Anatomical Therapeutic Chemical classification; E, events; ITTS, intention-to-treat set; n, number of patients; Ped-TMZ, temozolomide oral suspension (KIZFIZO®); TMZ, temozolomide; TMZ oral capsule, TEMODAL®.